Navigation Links
aTyr Pharma to Present at ChinaBio(R) Investor Forum in Hong Kong
Date:3/16/2009

Dr. James Cai, President of Hong Kong-based subsidiary Pangu BioPharma to Speak

SAN DIEGO, March 16 /PRNewswire/ -- aTyr Pharma, a privately held biopharmaceutical company focused on discovery and development of an entirely new class of natural protein therapeutics (biologics) for multiple disease indications, announced today that it will participate at the ChinaBio(R) Investor Forum in Hong Kong on 19 March 2009. Dr. James Cai, Senior Vice President of Clinical Development a aTyr Pharma and President of the Hong Kong based subsidiary Pangu BioPharma, will give an overview of aTyr's Discovery and Development program in the afternoon on Thursday, March 19th. The event will take place at the Hong Kong Science Park (http://www.chinabiollc.com/events/CBIF2009-HK/overview).

"aTyr Pharma and its Hong Kong subsidiary, Pangu BioPharma, are exactly the types of companies we seek out to present at our events," said Greg Scott, president and founder of ChinaBio LLC, organizer of the ChinaBio(R) Investor Forums. "aTyr's platform is strongly rooted in novel science, and Pangu is leveraging the best of China and Hong Kong through its research efforts here. We expect that aTyr will be very attractive to the over 50 VCs attending the Investor Forum."

aTyr has successfully raised Series A and Series B funds from leading U.S. based venture capital firms, including Alta Partners, Cardinal Partners and Polaris Venture Partners. In addition to supporting the company's continued platform discovery efforts, aTyr's management team is also preparing for preclinical development and Phase I studies for their first biologics drug candidate.

aTyr Pharma and Pangu BioPharma have a novel platform of naturally occurring protein fragments that can be developed into biologic agents for treating a wide variety of diseases. Capitalizing on the years of experience and discoveries made by founder Prof. Paul Schimmel, aTyr Pharma and Pangu BioPharma are identifying a broad platform of protein fragments derived from human aminoacyl tRNA synthetases. In his decades of research at MIT and now The Scripps Research Institute, Prof. Schimmel, has been a leader in discovering the many activities, roles and functions for this ancient class of enzymes and reported the first evidence that fragments and splice variants of these proteins have latent extracellular activities distinct from their intracellular roles in protein synthesis. With a wide variety of cell signaling activities, this class of unexplored peptides provides a reservoir of proteins with the potential to become blockbuster biotherapeutics ("Biologics").

Dr. Cai noted that "The ChinaBio Investors Forum provides a uniquely valuable platform for the leading biotech companies that are moving the China/Asia biotech community onto the global stage. It is a very motivating opportunity for me, helping investment groups identify the opportunity to share in the cutting edge of truly novel science while ultimately working towards better medicines for global patient populations."

About aTyr Pharma, Inc.

aTyr Pharma is a privately held biopharmaceutical company focused on identifying and developing a novel class of naturally occurring protein biologics for therapeutic application. aTyr's research facility is headquartered in San Diego, California, with offices in Hong Kong and Shanghai.

www.atyrpharma.com


'/>"/>
SOURCE aTyr Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
2. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
3. DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
6. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
7. BioCis Pharma Starts Phase IIa Trial in Psoriasis
8. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
9. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results
10. Advance Nanotechs Owlstone Announces First Pharmaceutical Industry Order
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , February 11, 2016 ... ("PositiveID" or "Company") (OTCQB: PSID), a life sciences ... that its Thermomedics subsidiary, which markets the Caregiver® ... growth plan in January 2016, including entering into ... sequential monthly sales growth, and establishing several near-term ...
(Date:2/10/2016)... Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... announce that Mitsui & Co. Ltd., its partner in ... plant, is investing an additional CDN$25 million in the ... stake from 30% to 40%.  Mitsui will also play ... produced in Sarnia , providing dedicated ...
(Date:2/10/2016)... (PRWEB) , ... February 10, ... ... REGN) today announced that it has joined the Human Vaccines Project, a ... infectious diseases and cancer. , The Human Vaccines Project brings together ...
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, a leading custom ... Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February 18, 2016. The ... for its annual event, which will run from 3:00 p.m. - 8:30 p.m. ...
Breaking Biology Technology:
(Date:2/1/2016)... , February 1, 2016 ... advancements to drive global touchfree intuitive gesture control market ... --> Rising sales of consumer electronics coupled with ... control market size through 2020 ... electronics coupled with new technological advancements to drive global ...
(Date:1/28/2016)... SAN JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: ... financial results for its second quarter ended December 31, 2015. ... the second quarter of fiscal 2016 increased 2 percent compared to ... the second quarter of fiscal 2016 was $35.0 million, or $0.93 ... Non-GAAP net income for the first quarter of fiscal 2016 ...
(Date:1/25/2016)... -- Glencoe Software, the world-leading supplier of image data management ... the data management solution OMERO Plus for the newly ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of cells, ... such as health and disease, the presence or absence ...
Breaking Biology News(10 mins):